# LiuXS Lab

Xue-Song Liu lab study the fundamental difference between cancer cell and normal somatic cell. With a purpose to identify cancer specific biomarkers and therapeutic targets. Multiple approaches, including cell biochemistry, bioinformatics and mouse modeling, are combined to investigate the basic mechanisms in cancer.

## Current research projects

1. Using cell biochemistry and genetic engineered mouse models to study the function of novel cancer related genes, including C7orf24/GGCT and others.  

1. Systematic study to identify biomarkers for cancer immunotherapy. See recent publication from our lab: [**Wang S, Jia M, He Z, Liu XS. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. *Oncogene*. 2018**](/publication/publication1/). 

1. Cancer genomic study to identify novel features and novel driving alterations for cancer evolution, with a specific focus on the function of non-coding DNA elements. 

1. Genetic engineered mouse model to faithfully mimic human cancer. CRISPR biotechnology enable us to generate multiple genetic alterations in somatic cell simultaneously to mimic real human cancer, which are usually driving by 4-5 genetic alterations.  

1. Combing high throughput sequencing techniques, super-resolution microscope or most advanced biotechnology to study the chromatin structure alterations during the evolution of human cancer.  


## Join us

Welcome graduate or undergraduate students to contact Professor Liu:

* email: <liuxs@shanghaitech.edu.cn>
* Phone: 20684520  
* Address: L building A406 of ShanghaiTech. University 


## Members

![](/img/group1.jpg)

![](/img/group2.jpg)

**PI**

* Xue-Song Liu

Graduate students

* Jing Zhang
* Shixiang Wang 
* Zaoke He. 

Lab manager 

* Yuanyuan Shao.

Postdoc 

* Yuxing Chen

Undergraduate students

* Qi Zhu
* Jiayue Zhao
* Lu Yang
* Zhaoyang Jiang  

Lab alumni

* Xiaolin Wu
* Da Xie. 

## Publications

1. Wang S, Jia M, He Z, Liu XS. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 2018 Apr 26. doi: 10.1038/s41388-018-0245-9. 

1. Ming Chen, Jiangwen Zhang, Katia Sampieri, John G. Clohessy, Lourdes Mendez, Enrique Gonzalez-Billalabeitia, Xue-Song Liu, Yu-Ru Lee, Jacqueline Fung, Jesse M. Katon, Archita Venugopal Menon, Kaitlyn A. Webster, Christopher Ng, Maria Dilia Palumbieri , Moussa S. Diolombi, Susanne B. Breitkopf, Julie Teruya-Feldstein, Sabina Signoretti, Roderick T. Bronson, John M. Asara, Mireia Castillo-Martin, Carlos Cordon-Cardo, Pier Paolo Pandolfi. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. 

1. Gerarduzzi C, de Polo A, Liu XS, El Kharbili M, Little JB, Yuan ZM. Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE. J Biol Chem. 2016 Dec 9;291(50):25937-25949. 

1. Liu XS, Liu Z, Gerarduzzi C, Choi DE, Ganapathy S, Pandolfi PP, Yuan ZM. Somatic human ZBTB7A zinc finger mutations promote cancer progression. Oncogene. 2015 Oct 12. doi: 10.1038/onc.2015.371.

1. Liu XS, Chandramouly G, Rass E, Guan Y, Wang G, Hobbs RM, Rajendran A, Xie A, Shah JV, Davis AJ, Scully R, Lunardi A, Pandolfi PP. LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair. Nature Communications. 2015 Oct 8; 6:8325. doi: 10.1038/ncomms9325. 

**_Publications before joining Shanghaitech_**:  

1. Liu XS, Genet MD, Haines JE, Mehanna EK, Wu S, Chen HI, Chen Y, Qureshi AA, Han J, Chen X, Fisher DE, Pandolfi PP, Yuan ZM. ZBTB7A suppresses melanoma metastasis by transcriptionally repressing MCAM. Mol Cancer Res. 2015, 13(8):1206-17.

1. Liu XS, Little JB, Yuan ZM. Glycolytic metabolism influences global chromatin structure. Oncotarget. 2015, 6(6):4214-25.

1. Liu XS, Haines JE, Mehanna EK, Genet MD, Ben-Sahra I, Asara JM, Manning BD, Yuan ZM. ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis. Genes Dev. 2014, 28(17):1917-28. (Highlighted in Nature Reviews Cancer: Isabel Lokody,	Nature Reviews Cancer, 14, 649 (2014))  

1. González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014, 4(8):896-904. 

1. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. 2013, 45(7):739-46. 

1. Zhang HX, Liu ZX, Sun YP, Zhu J, Lu SY, Liu XS, Huang QH, Xie YY, Zhu HB, Dang SY, Chen HF, Zheng GY, Li YX, Kuang Y, Fei J, Chen SJ, Chen Z, Wang ZG. Rig-I regulates NF-κB activity through binding to Nf-κb1 3'-UTR mRNA. Proc Natl Acad Sci U S A. 2013, 110(16):6459-64. 

1. Liu XS\*, Zhao XD\*, Wang X\*, Yao YX, Zhang LL, Shu RZ, Ren WH, Huang Y, Huang L, Gu MM, Kuang Y, Wang L, Lu SY, Chi J, Fen JS, Wang YF, Fei J, Dai W, Wang ZG. Germinal Cell Aplasia in Kif18a Mutant Male Mice Due to Impaired Chromosome Congression and Dysregulated BubR1 and CENP-E. Genes Cancer. 2010, 1(1):26-39. (\* co-first author) (Highlighted as cover story) 

1. Shu RZ, Zhang F, Liu XS, Li CL, Wang L, Tai YL, Wu XL, Yang X, Liao XD, Jin Y, Gu MM, Huang L, Pang XF, Wang ZG. Target deletion of the cytoskeleton-associated protein palladin does not impair neurite outgrowth in mice. PLoS One. 2009, 4(9):e6916. 

1. Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, Xu JQ, Cui B, Wang L, Lu SY, Chen XY, Zhang HG, Huang W, Yuan WT, Yang JM, Gu Q, Fei J, Chen Z, Yuan ZM, Wang ZG. Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene. Am J Hum Genet. 2009, 85(1):53-63. 

1. Wang Y, Zhang HX, Sun YP, Liu ZX, Liu XS, Wang L, Lu SY, Kong H, Liu QL, Li XH, Lu ZY, Chen SJ, Chen Z, Bao SS, Dai W, Wang ZG. Rig-I-/- mice develop colitis associated with downregulation of G alpha i2. Cell Res. 2007, 17(10):858-68.

1. Liu XS, Li XH, Wang Y, Shu RZ, Wang L, Lu SY, Kong H, Jin YE, Zhang LJ, Fei J, Chen SJ, Chen Z, Gu MM, Lu ZY, Wang ZG. Disruption of palladin leads to defects in definitive erythropoiesis by interfering with erythroblastic island formation in mouse fetal liver. Blood. 2007, 110(3):870-76. 

1. Liu XS, Luo HJ, Yang H, Wang L, Kong H, Jin YE, Wang F, Gu MM, Chen Z, Lu ZY, Wang ZG. Palladin regulates cell and extracellular matrix interaction through maintaining normal actin cytoskeleton architecture and stabilizing beta1-integrin. J Cell Biochem. 2007, 100(5):1288-300.

1. Luo H\*, Liu X\*, Wang F, Huang Q, Shen S, Wang L, Xu G, Sun X, Kong H, Gu M, Chen S, Chen Z, Wang Z. Disruption of palladin results in neural tube closure defects in mice. Mol Cell Neurosci. 2005, 29(4):507-15. (\* co-first author)
